Evicenter
Vabysmo (faricimab-svoa) in Neovascular age-related macular degeneration
Manufacturer
Genentech, Inc.
Prescribing information
Vabysmo (opens in a new tab)
Questions
12
Last updated

All questions

Safety: Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration

5 questions · 1 source

Side effects

What side effects did Vabysmo cause in wet AMD trials?

Note: Table 1 columns are VABYSMO in AMD (N=664), DME (N=1,262), and RVO (N=641), then aflibercept in AMD (N=662), DME (N=625), and RVO (N=635), in that order; the AMD columns are the wet AMD trials (TENAYA and LUCERNE).

How common are cataracts with Vabysmo in wet AMD trials?

Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.

Can Vabysmo cause retinal pigment epithelial tears in wet AMD?

Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the second is aflibercept in AMD (N=662).

How common is eye inflammation with Vabysmo in wet AMD trials?

Note: In the Table 1 row, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.

Warnings

Does Vabysmo raise stroke or heart attack risk in wet AMD?